About MCMi Professional Development
Through professional development, FDA meets the regulatory challenges posed by new science and technology developments.
Through professional development, FDA meets the regulatory challenges posed by new science and technology developments. In addition to supporting a broad regulatory science program—including professional development components—FDA fosters collaborative activities with scientific institutions, academia, and industry.
Lectures, training courses and symposia
The FDA Medical Countermeasures Initiative (MCMi) supports lectures that cover a range of topics including guidance development, the policies, procedures, and framework for assessing applications for review, and other timely medical countermeasure (MCM)-related topics. Lectures include:
Foundations for Preclinical Review
Lecture series to engage subject matter experts from FDA Centers and offices on issues related to obtaining valid, reliable animal models for human disease. Goals include examining common study pitfalls and supporting consistent guidance development.
MCMi Lecture Series
Periodic presentations to broaden understanding of the policies, procedures, and U.S. governmental framework for FDA reviewers assessing applications for medical products to counter chemical, biological, radiological, and nuclear (CBRN) threats and emerging infectious diseases.
Training course: Achieving Data Quality and Integrity in Maximum Containment Laboratories (Bethesda, MD)
To help address the challenges associated with ensuring data quality and integrity in regulated studies conducted in BSL-4 laboratories to support MCM development, FDA and the University of Texas Medical Branch, Galveston National Laboratory (UTMB) collaborate to provide a week-long annual training course on how to meet GLP requirements in BSL-4 facilities.
Training Course: Achieving Data Quality and Integrity in Clinical Trials Involving High Consequence Pathogens
This annual course, hosted by FDA and UTMB, focuses on the preparation and execution of research clinical trials to facilitate the approval of MCMs for high-consequence pathogens.
MCMi Regulatory Science Symposium
For several years (2012-2014), MCMi sponsored an annual regulatory science symposium [ARCHIVED] to exchange ideas on MCM development and explore the latest research. Webcast recordings are available. In 2015, in lieu of a separate MCMi symposium, FDA began hosting a more comprehensive FDA Science Forum to discuss a wide variety of topics, including medical countermeasure-related research.
FDA Science Forum
Every two years, FDA hosts the FDA Science Forum, featuring an opportunity for the public to view the unique scientific research and collaborative efforts of FDA’s 11,000 scientists across a wide range of disciplines. Sessions include updates on medical countermeasures, infectious disease, pathogen reduction technologies, novel technologies, product development, manufacturing, and more.
Advancing skills of FDA staff with continuing education
The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) contains key legal authorities to sustain and strengthen our Nation's preparedness for public health emergencies involving chemical, biological, radiological, and nuclear (CBRN) agents, as well as emerging infectious disease threats. PAHPRA provisions focusing on FDA's interactions with government and industry working to develop MCMs help ensure that FDA personnel involved in review of applications for MCMs have sufficient background information, training, and expertise.
FDA recruits and fosters top talent by providing innovative skill development programs to prepare staff to successfully address the regulatory challenges presented by new areas of science and medicine. MCMi offers continuing education credits to physicians, nurses, pharmacists, and veterinarians who attend selected professional development activities.
FDA hosts numerous public meetings and workshops each year. For MCM-related events, visit our News and Events page.